Anti-alk antibodies and uses thereof
AssigneeTrellis Bioscience, LLC
InventorsAngeles Estelles, Mikhail Gishizky, Stefan Ryser, Lawrence Kauvar
Life of this patent
Estimating the term…
Loading patent…
AssigneeTrellis Bioscience, LLC
InventorsAngeles Estelles, Mikhail Gishizky, Stefan Ryser, Lawrence Kauvar
Estimating the term…
Disclosed herein are monoclonal antibodies, and antigen-binding fragments thereof, that immunospecifically bind to human Anaplastic Lymphoma Kinase (ALK). Also provided are methods of use thereof, such the treatment of cancer. Also included are antibody-drug conjugates (ADCs) including the monoclonal antibodies and/or antigen-binding fragments thereof, linked to an effector agent, such as a cytotoxic agent. Also provided are method of using such ADCs. Nucleic acid molecules, vectors, and host cells for the monoclonal antibodies and antigen-binding fragments thereof are also provided, as are pharmaceutical and veterinarian compositions including the monoclonal antibodies, and antigen-binding fragments thereof, and/or the associated ADCs.
An isolated monoclonal antibody (mAb) or antigen binding fragment thereof that specifically binds Anaplastic Lymphoma Kinase (ALK), the mAb or antigen binding fragment thereof comprising a heavy chain variable region (VH) as set forth in the amino acid sequence corresponding to SEQ ID NO:1 and a light chain variable (VL) region as set forth in the amino acid sequence corresponding SEQ ID NO:
-9. (canceled)
-22. (canceled)
An isolated monoclonal antibody (mAb) or antigen binding fragment thereof that specifically binds Anaplastic Lymphoma Kinase (ALK), the isolated mAb or antigen binding fragment thereof comprising heavy chain variable region and a light chain variable region, wherein
(canceled)
-29. (canceled)
-32. (canceled)
-35. (canceled)
An isolated nucleic acid, or a plurality of isolated nucleic acids, wherein the isolated nucleic acid comprises, or the plurality of isolated nucleic acids comprise, a sequence that is 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the nucleic acid sequence set forth in SEQ ID NOS:
(canceled)
A method of treating cancer, the method comprising administering to a subject any one or more nucleic acid sequences that encode the amino acid sequence set forth as SEQ ID NOS:
(canceled)
Dependencies are inferred from the claim text.